<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115063">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605266</url>
  </required_header>
  <id_info>
    <org_study_id>1000021384</org_study_id>
    <nct_id>NCT01605266</nct_id>
  </id_info>
  <brief_title>INSIGHT (Insight Into Nephrotic Syndrome)</brief_title>
  <acronym>INSIGHT</acronym>
  <official_title>INSIGHT (Insight Into Nephrotic Syndrome: Investigating Genes, Health and Therapeutics)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      INSIGHT is a longitudinal study of childhood nephrotic syndrome to determine genetic,
      serologic and environmental factors contributing to nephrotic syndrome and disease
      progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INSIGHT is a longitudinal observational study of childhood nephrotic syndrome to determine
      genetic, serologic and environmental factors contributing to nephrotic syndrome and disease
      progression. This is a large multiethnic cohort to test hypotheses of gene and environmental
      risk factors and disease progression. Participants are recruited from Toronto, Ontario and
      surrounding regions. Additional sites will be added on in the future.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse (number of relapses)</measure>
    <time_frame>Entire follow-up</time_frame>
    <description>After remission, an increase in the first AM morning urine protein â‰¥ 3+ for 3 consecutive days or increase in maintenance prednisone dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequently relapsing NS (yes or no)</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
    <description>4 or more relapses within any 12 month interval OR 2 or more relapses within the first 6 months since diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid - dependent NS (yes or no)</measure>
    <time_frame>6, 12, 18 and 24 months</time_frame>
    <description>2 relapses during steroid taper or a relapse within 14 days of steroid discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial Steroid Resistance (yes or no)</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Commencing second line medication due to no response from prednisone with initial treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CKD (yes or no)</measure>
    <time_frame>Entire follow-up</time_frame>
    <description>eGFR less than or equal to 60mg/ml/1.73m^2 for 3 or more consecutive months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESRD (yes or no)</measure>
    <time_frame>Entire follow-up</time_frame>
    <description>eGFR less than or equal to 15 mg/ml/1.73m^2, or initiation of dialysis or receiving a transplant.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Nephrotic Syndrome</arm_group_label>
    <description>The cohort includes all children diagnosed with nephrotic syndrome between ages 1-18. Children and their caregiver must be willing to provide informed consent, complete questionnaires, and provide biospecimens of the child. Those with secondary causes of nephrotic syndrome and/or systemic disease are excluded.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood is drawn for DNA, serum, plasma, buffy coat and whole blood. Urine and toenail
      clippings are also collected.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children with nephrotic syndrome. Children are recruited from Toronto and surrounding
        region with additional sites added later.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. diagnosis of nephrotic syndrome

          2. signed informed consent and assent appropriate for age

          3. ages 1-18 years old and

          4. ability to complete questionnaires

        Exclusion Criteria:

          1. congenital nephrotic syndrome (less than age 1)

          2. syndromic disease with multiple organ involvement

          3. inability to provide consent by primary care providers

          4. conditions such as systemic lupus erythematous.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rulan Parekh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rulan Parekh, MD</last_name>
    <phone>416-813-7654</phone>
    <phone_ext>306459</phone_ext>
    <email>rulan.parekh@sickkids.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>William Osler Health System, Brampton Civic Hospital</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rachel J Pearl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rulan Parekh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diane Hebert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Licht, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rouge Valley Health System, Rouge Valley Centenary</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1E 4B9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hubert Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rulan Parekh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diane Hebert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Strug, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Licht, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rulan Parekh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diane Hebert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Strug, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Licht, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valerie Langlois, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien Noone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23351121</url>
    <description>PubMed: The rationale and design of Insight into Nephrotic Syndrome: Investigating Genes, Health and Therapeutics (INSIGHT): a prospective cohort study of childhood nephrotic syndrome.</description>
  </link>
  <reference>
    <citation>Hussain N, Zello JA, Vasilevska-Ristovska J, Banh TM, Patel VP, Patel P, Battiston CD, Hebert D, Licht CP, Piscione TD, Parekh RS. The rationale and design of Insight into Nephrotic Syndrome: Investigating Genes, Health and Therapeutics (INSIGHT): a prospective cohort study of childhood nephrotic syndrome. BMC Nephrol. 2013 Jan 26;14:25. doi: 10.1186/1471-2369-14-25.</citation>
    <PMID>23351121</PMID>
  </reference>
  <reference>
    <citation>Borges K, Vasilevska-Ristovska J, Hussain-Shamsy N, Patel V, Banh T, Hebert D, Pearl RJ, Radhakrishnan S, Piscione TD, Licht CP, Langlois V, Levin L, Strug L, Parekh RS. Parental attitudes to genetic testing differ by ethnicity and immigration in childhood nephrotic syndrome: a cross-sectional study. Can J Kidney Health Dis. 2016 Mar 17;3:16. doi: 10.1186/s40697-016-0104-y. eCollection 2016 Mar 17.</citation>
    <PMID>26998310</PMID>
  </reference>
  <results_reference>
    <citation>Banh TH, Hussain-Shamsy N, Patel V, Vasilevska-Ristovska J, Borges K, Sibbald C, Lipszyc D, Brooke J, Geary D, Langlois V, Reddon M, Pearl R, Levin L, Piekut M, Licht CP, Radhakrishnan S, Aitken-Menezes K, Harvey E, Hebert D, Piscione TD, Parekh RS. Ethnic Differences in Incidence and Outcomes of Childhood Nephrotic Syndrome. Clin J Am Soc Nephrol. 2016 Jul 21. pii: CJN.00380116. [Epub ahead of print]</citation>
    <PMID>27445165</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 1, 2017</lastchanged_date>
  <firstreceived_date>April 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Rulan Parekh</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>kidney disease</keyword>
  <keyword>minimal change disease</keyword>
  <keyword>focal segmental glomerulosclerosis</keyword>
  <keyword>nephrotic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
